{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001664","form_type":"8-K","ticker":null,"cik":"0001173281","company_name":"NeuBase Therapeutics, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.082044+00:00","generated_at":"2026-05-28T07:54:04.029046+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NeuBase approves $0.13/share initial distribution in liquidation; CEO/CFO resigns, board change","bullets":["Todd Branning resigns as Interim CEO and CFO effective Jan 3, 2025; appointed to Board on Jan 4.","Dov Goldstein resigns from Board effective immediately on Jan 4, 2025.","Board approved Plan of Distribution: initial distribution of ~$500,000 ($0.13 per share) to stockholders of record June 26, 2024.","Company is in process of dissolution; shares delisted from Nasdaq in May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001664","json":"https://secwatch.observer/filing/0001104659-25-001664.json","markdown":"https://secwatch.observer/filing/0001104659-25-001664.md","text":"https://secwatch.observer/filing/0001104659-25-001664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/tm252159d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:54:04.029046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"400a206dbd","claim":"Todd P. Branning was appointed as Director at NeuBase Therapeutics, Inc..","evidence_excerpt":"On January 4, 2025, Mr. Branning was appointed to the Board of Directors of the Company (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9a3d1dfc3e","claim":"Todd P. Branning resigned as Interim Chief Executive Officer and Chief Financial Officer at NeuBase Therapeutics, Inc..","evidence_excerpt":"Todd P. Branning, the Interim Chief Executive Officer and Chief Financial Officer of NeuBase Therapeutics, Inc. (the “Company”), notified the Company of his resignation as interim Chief Executive Officer and Chief Financial Officer, effective as of close of business on January 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Executive Officer and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c5207e5ebc","claim":"Dov A. Goldstein resigned as Director at NeuBase Therapeutics, Inc..","evidence_excerpt":"On January 4, 2025, Dov A. Goldstein, M.D. notified the Company of his resignation as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465925001664/0001104659-25-001664-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}